Current Report Filing (8-k)

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): December 21, 2016

 

EYEGATE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-36672		98-0443284
(Commission File Number)		(IRS Employer Identification No.)
271 Waverley Oaks Road Suite 108 Waltham, MA		02452
(Address of principal executive offices)		(Zip Code)

 

[phone]

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously reported, on December 19, 2016 (the “Separation Date”), Ryan Brenneman ceased serving as the Chief Financial Officer of EyeGate Pharmaceuticals, Inc. (the “Company”). On December 21, 2016, the Company and Mr. Brenneman entered into a Separation Agreement (the “Separation Agreement”) with an effective date as of December 29, 2016. The Separation Agreement provides that, among other things, if Mr. Brenneman does not revoke his acceptance of the Separation Agreement within the applicable seven-day revocation period, (a) Mr. Brenneman will receive his base salary for a period of four months, and (b) the Company will pay the full premium amount for COBRA continuation coverage for a period of three months, subject to certain conditions. The Separation Agreement also contains a general release in favor of the Company.

 

The foregoing is a summary only and does not purport to be a complete description of all of the terms, provisions, covenants and agreements contained in the Separation Agreement, and is subject to and qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated by reference herein.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d) Exhibits.

 

The Company hereby files the following exhibit:

 

10.1	Separation Agreement, dated as of December 21, 2016, between the Company and Ryan Brenneman.

  

2  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

	EYEGATE PHARMACEUTICALS, INC.
	By:	/s/ Stephen From
		Stephen From
		President and Chief Executive Officer
	Date: December 22, 2016

  

3  

 

 

Exhibit Index

 

10.1	Separation Agreement, dated as of December 21, 2016, between the Company and Ryan Brenneman.

 

4